In Russia, another drug for COVID-19 based on Japanese favipiravir is brought to the market for outpatient use, promising that it will be cheaper than analogues, the cost of which was exceeded by the cost of living of Russians. It was stated that Avifavir, announced by the Russian Direct Investment Fund, will be 30% cheaper, that is, if rival drugs cost about 12 thousand rubles, the cost of the third will be about 8 thousand rubles. Can such a price be called accessible to the population if, according to the results of 2019, almost 18 million Russians live below the poverty line? the news agency tried to figure out who is the ultimate recipient of profits from sales of this drug, positioned as the first in the country approved for the treatment of COVID-19. Mann Vissenbjerg Männern Mit Sex